Latest News

DystropHix earns FDA Designation: Rare Pediatric Disease (RPD)

DystropHix Eligible For One of the Last FDA Rare Pediatric Disease Vouchers Before Program Sunsets

DystropHix earns FDA Orphan Disease Designation (ODD)

DystroHix earns FDA Orphan Disease Designation (ODD)

Video: "Getting a Drug to Market" by Dr. Aaron Morton

Dr. Aaron Morton presents at Texas A&M College of Education & Human Development

Sixteen Research Teams At Texas A&M Receive Innovation Awards

Advancing Discovery to Market provides $3.55 million in grants for transforming recent discoveries into new products with commercial potential.

Video: Huffines Institute 297- "Bench to Bedside" with Dr. Aaron Morton

Dr. Aaron Morton is interviewed by the Huffines Institute

DystropHix Research Funded by Coulter Biomedical Accelerator

Local, Structural Scaffold to Stabilize Limb Muscle in Muscular Dystrophy